Semin Neurol 2021; 41(05): 511-529
DOI: 10.1055/s-0041-1733792
Review Article

Evaluation and Management of Acute Myelopathy

Elia Sechi
1   Department of Neurology, Mayo Clinic, Rochester, Minnesota
,
1   Department of Neurology, Mayo Clinic, Rochester, Minnesota
2   Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
› Author Affiliations

Abstract

Acute myelopathies are spinal cord disorders characterized by a rapidly progressive course reaching nadir within hours to a few weeks that may result in severe disability. The multitude of underlying etiologies, complexities in confirming the diagnosis, and often unforgiving nature of spinal cord damage have always represented a challenge. Moreover, certain slowly progressive myelopathies may present acutely or show abrupt worsening in specific settings and thus further complicate the diagnostic workup. Awareness of the clinical and magnetic resonance imaging characteristics of different myelopathies and the specific settings where they occur is fundamental for a correct diagnosis. Neuroimaging helps distinguish compressive etiologies that may require urgent surgery from intrinsic etiologies that generally require medical treatment. Differentiation between various myelopathies is essential to establish timely and appropriate treatment and avoid harm from unnecessary procedures. This article reviews the contemporary spectrum of acute myelopathy etiologies and provides guidance for diagnosis and management.



Publication History

Article published online:
07 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Flanagan EP, Pittock SJ. Diagnosis and management of spinal cord emergencies. Handb Clin Neurol 2017; 140: 319-335
  • 2 Dubey D, Pittock SJ, Krecke KN. et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 2019; 76 (03) 301-309
  • 3 Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59 (04) 499-505
  • 4 Zalewski NL, Flanagan EP, Keegan BM. Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology 2018; 90 (02) e96-e102
  • 5 Ahuja CS, Wilson JR, Nori S. et al. Traumatic spinal cord injury. Nat Rev Dis Primers 2017; 3: 17018
  • 6 Lee BB, Cripps RA, Fitzharris M, Wing PC. The global map for traumatic spinal cord injury epidemiology: update 2011, global incidence rate. Spinal Cord 2014; 52 (02) 110-116
  • 7 Griffin MR, Opitz JL, Kurland LT, Ebersold MJ, O'Fallon WM. Traumatic spinal cord injury in Olmsted County, Minnesota, 1935-1981. Am J Epidemiol 1985; 121 (06) 884-895
  • 8 Young J, Quinn S, Hurrell M, Taylor B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Mult Scler 2009; 15 (11) 1295-1302
  • 9 Chung KK, Altmann D, Barkhof F. et al. A 30-year clinical and magnetic resonance imaging observational study of multiple sclerosis and clinically isolated syndromes. Ann Neurol 2020; 87 (01) 63-74
  • 10 Sechi E, Shosha E, Williams JP. et al. Aquaporin-4 and MOG autoantibody discovery and idiopathic transverse myelitis epidemiology. Neurology 2019; 93 (04) e414-e420
  • 11 Ptaszynski AE, Hooten WM, Huntoon MA. The incidence of spontaneous epidural abscess in Olmsted County from 1990 through 2000: a rare cause of spinal pain. Pain Med 2007; 8 (04) 338-343
  • 12 Flanagan EP, Cabre P, Weinshenker BG. et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016; 79 (05) 775-783
  • 13 Senanayake B, Jitprapaikulsan J, Aravinthan M. et al. Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. J Neurol Neurosurg Psychiatry 2019; 90 (12) 1381-1383
  • 14 Zalewski NL, Rabinstein AA, Krecke KN. et al. Characteristics of spontaneous spinal cord infarction and proposed diagnostic criteria. JAMA Neurol 2019; 76 (01) 56-63
  • 15 Messacar K, Schreiner TL, Van Haren K. et al. Acute flaccid myelitis: a clinical review of US cases 2012-2015. Ann Neurol 2016; 80 (03) 326-338
  • 16 Suanprasert N, Taylor BV, Klein CJ. et al. Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis. Mult Scler Relat Disord 2019; 30: 284-290
  • 17 Ropper AE, Ropper AH. Acute spinal cord compression. N Engl J Med 2017; 376 (14) 1358-1369
  • 18 Hedera P. Hereditary myelopathies. Continuum (Minneap Minn) 2018; 24 (2, Spinal Cord Disorders): 523-550
  • 19 Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012; 69 (08) 1026-1031
  • 20 Savoldi F, Nasr Z, Hu W. et al. McArdle sign: a specific sign of multiple sclerosis. Mayo Clin Proc 2019; 94 (08) 1427-1435
  • 21 Sechi E, Krecke KN, Pittock SJ. et al. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler 2021; 27 (02) 303-308
  • 22 Paul P, McKeon A, Pittock SJ. et al. GFAP IgG associated inflammatory polyneuropathy. J Neuroimmunol 2020; 343: 577233
  • 23 Vazquez Do Campo R, Stephens A, Marin Collazo IV, Rubin DI. MOG antibodies in combined central and peripheral demyelination syndromes. Neurol Neuroimmunol Neuroinflamm 2018; 5 (06) e503
  • 24 Sechi G, Sechi E, Fois C, Kumar N. Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. Nutr Rev 2016; 74 (05) 281-300
  • 25 Flanagan EP, Hinson SR, Lennon VA. et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 2017; 81 (02) 298-309
  • 26 Grill MF. Infectious myelopathies. Continuum (Minneap Minn) 2018; 24 (2, Spinal Cord Disorders): 441-473
  • 27 Stern BJ, Royal III W, Gelfand JM. et al. Definition and consensus diagnostic criteria for neurosarcoidosis: from the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol 2018; 75 (12) 1546-1553
  • 28 Flanagan EP, O'Neill BP, Porter AB, Lanzino G, Haberman TM, Keegan BM. Primary intramedullary spinal cord lymphoma. Neurology 2011; 77 (08) 784-791
  • 29 Sechi E, Addis A, Batzu L. et al. Late presentation of NMOSD as rapidly progressive leukoencephalopathy with atypical clinical and radiological findings. Mult Scler 2018; 24 (05) 685-688
  • 30 Cobo-Calvo A, Ruiz A, Maillart E. et al; OFSEP and NOMADMUS Study Group. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 2018; 90 (21) e1858-e1869
  • 31 Shosha E, Dubey D, Palace J. et al. Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology 2018; 91 (17) e1642-e1651
  • 32 Uygunoglu U, Zeydan B, Ozguler Y. et al. Myelopathy in Behçet's disease: the Bagel sign. Ann Neurol 2017; 82 (02) 288-298
  • 33 Berkowitz AL, Samuels MA. The neurology of Sjogren's syndrome and the rheumatology of peripheral neuropathy and myelitis. Pract Neurol 2014; 14 (01) 14-22
  • 34 Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009; 60 (11) 3378-3387
  • 35 Zheng Y, Zhang Y, Cai M, Lai N, Chen Z, Ding M. Central nervous system involvement in ANCA-associated vasculitis: what neurologists need to know. Front Neurol 2019; 9: 1166
  • 36 Kaufman DM, Kaplan JG, Litman N. Infectious agents in spinal epidural abscesses. Neurology 1980; 30 (08) 844-850
  • 37 Flanagan EP, Kaufmann TJ, Krecke KN. et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79 (03) 437-447
  • 38 Sechi E, Morris PP, McKeon A. et al. Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J Neurol Neurosurg Psychiatry 2019; 90 (04) 488-490
  • 39 AbdelRazek MA, Mowla A, Farooq S, Silvestri N, Sawyer R, Wolfe G. Fibrocartilaginous embolism: a comprehensive review of an under-studied cause of spinal cord infarction and proposed diagnostic criteria. J Spinal Cord Med 2016; 39 (02) 146-154
  • 40 Di Lazzaro V, Restuccia D, Oliviero A. et al. Ischaemic myelopathy associated with cocaine: clinical, neurophysiological, and neuroradiological features. J Neurol Neurosurg Psychiatry 1997; 63 (04) 531-533
  • 41 Chang CW, Donovan DJ, Liem LK. et al. Surfers' myelopathy: a case series of 19 novice surfers with nontraumatic myelopathy. Neurology 2012; 79 (22) 2171-2176
  • 42 Decker ML, Emery DJ, Smyth PS, Lu JQ, Lacson A, Yacyshyn E. Microscopic polyangiitis with spinal cord involvement: a case report and review of the literature. J Stroke Cerebrovasc Dis 2016; 25 (07) 1696-1704
  • 43 Galetta SL, Balcer LJ, Lieberman AP, Syed NA, Lee JM, Oberholtzer JC. Refractory giant cell arteritis with spinal cord infarction. Neurology 1997; 49 (06) 1720-1723
  • 44 Sveinsson O, Herrman L, Hietala MA. Heroin-induced acute myelopathy with extreme high levels of CSF glial fibrillar acidic protein indicating a toxic effect on astrocytes. BMJ Case Rep 2017; 2017: bcr-2017-219903
  • 45 Mastaglia FL, McCallum RI, Walder DN. Myelopathy associated with decompression sickness: a report of six cases. Clin Exp Neurol 1983; 19: 54-59
  • 46 Leep Hunderfund AN, Wijdicks EF. Intramedullary spinal cord hemorrhage (hematomyelia). Rev Neurol Dis 2009; 6 (02) E54-E61
  • 47 Raasck K, Habis AA, Aoude A. et al. Spontaneous spinal epidural hematoma management: a case series and literature review. Spinal Cord Ser Cases 2017; 3: 16043
  • 48 Sotoca J, Rodríguez-Álvarez Y. COVID-19-associated acute necrotizing myelitis. Neurol Neuroimmunol Neuroinflamm 2020; 7 (05) e803
  • 49 Kira J, Kawano Y, Yamasaki K, Tobimatsu S. Acute myelitis with hyperIgEaemia and mite antigen specific IgE: atopic myelitis. J Neurol Neurosurg Psychiatry 1998; 64 (05) 676-679
  • 50 Young WF. Cervical spondylotic myelopathy: a common cause of spinal cord dysfunction in older persons. Am Fam Physician 2000; 62 (05) 1064-1070 , 1073
  • 51 Joanes V. Cervical disc herniation presenting with acute myelopathy. Surg Neurol 2000; 54 (02) 198
  • 52 Murphy OC, Salazar-Camelo A, Jimenez JA. et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol Neuroimmunol Neuroinflamm 2020; 7 (04) e722
  • 53 Flanagan EP, McKeon A, Lennon VA. et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 2011; 76 (24) 2089-2095
  • 54 Murphy OC, Hedjoudje A, Salazar-Camelo A, Pardo CA, Gailloud P. Clinical characteristics, misdiagnosis and outcomes of patients with low-flow spinal arteriovenous fistulas. J Neurol Sci 2020; 413: 116863
  • 55 Pandey S, Holla VV, Rizvi I, Qavi A, Shukla R. Can vitamin B12 deficiency manifest with acute posterolateral or posterior cord syndrome?. Spinal Cord Ser Cases 2016; 2: 16006
  • 56 Yuan JL, Wang SK, Jiang T, Hu WL. Nitrous oxide induced subacute combined degeneration with longitudinally extensive myelopathy with inverted V-sign on spinal MRI: a case report and literature review. BMC Neurol 2017; 17 (01) 222
  • 57 Huemer M, Scholl-Bürgi S, Hadaya K. et al. Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy. Orphanet J Rare Dis 2014; 9: 161
  • 58 Girard B, Bonnemains C, Schmitt E, Raffo E, Bilbault C. Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: a treatable disease. Mult Scler 2017; 23 (01) 119-122
  • 59 Graber JJ, Nolan CP. Myelopathies in patients with cancer. Arch Neurol 2010; 67 (03) 298-304
  • 60 Wong CS, Van Dyk J, Milosevic M, Laperriere NJ. Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys 1994; 30 (03) 575-581
  • 61 Wong CS, Fehlings MG, Sahgal A. Pathobiology of radiation myelopathy and strategies to mitigate injury. Spinal Cord 2015; 53 (08) 574-580
  • 62 Sechi EM, Markovic SN, McKeon A. et al. Neurological autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 2020; 95 (17) e2442-e2452
  • 63 Bradshaw MJ, Mobley BC, Zwerner JP, Sriram S. Autopsy-proven demyelination associated with infliximab treatment. Neurol Neuroimmunol Neuroinflamm 2016; 3 (02) e205
  • 64 Kunchok A, Aksamit Jr AJ, Davis III JM. et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol 2020; 77 (08) 937-946
  • 65 Cohen DA, Lopez-Chiriboga AS, Pittock SJ. et al. Posttransplant autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2018; 5 (06) e497
  • 66 Montalva-Iborra A, Alcanyis-Alberola M, Grao-Castellote C, Torralba-Collados F, Giner-Pascual M. Risk factors in iatrogenic spinal cord injury. Spinal Cord 2017; 55 (09) 818-822
  • 67 Gialdini G, Parikh NS, Chatterjee A. et al. Rates of spinal cord infarction after repair of aortic aneurysm or dissection. Stroke 2017; 48 (08) 2073-2077
  • 68 Lapuyade B, Sibon I, Jeanin S, Dousset V. Neurological picture. Spinal cord involvement in posterior reversible encephalopathy syndrome. J Neurol Neurosurg Psychiatry 2009; 80 (01) 35
  • 69 Magaña SM, Matiello M, Pittock SJ. et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72 (08) 712-717
  • 70 Flanagan EP. Autoimmune myelopathies. Handb Clin Neurol 2016; 133: 327-351
  • 71 Post MJ, Becerra JL, Madsen PW. et al. Acute spinal subdural hematoma: MR and CT findings with pathologic correlates. AJNR Am J Neuroradiol 1994; 15 (10) 1895-1905
  • 72 Song KJ, Choi BW, Kim GH, Kim JR. Clinical usefulness of CT-myelogram comparing with the MRI in degenerative cervical spinal disorders: is CTM still useful for primary diagnostic tool?. J Spinal Disord Tech 2009; 22 (05) 353-357
  • 73 Diehn FE, Maus TP, Morris JM. et al. Uncommon manifestations of intervertebral disk pathologic conditions. Radiographics 2016; 36 (03) 801-823
  • 74 Koeller KK, Rosenblum RS, Morrison AL. Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation. Radiographics 2000; 20 (06) 1721-1749
  • 75 Flanagan EP, Krecke KN, Marsh RW, Giannini C, Keegan BM, Weinshenker BG. Specific pattern of gadolinium enhancement in spondylotic myelopathy. Ann Neurol 2014; 76 (01) 54-65
  • 76 Conway BL, Clarke MJ, Kaufmann TJ, Flanagan EP. Utility of extension views in spondylotic myelopathy mimicking transverse myelitis. Mult Scler Relat Disord 2017; 11: 62-64
  • 77 Asnafi S, Morris PP, Sechi E. et al. The frequency of longitudinally extensive transverse myelitis in MS: a population-based study. Mult Scler Relat Disord 2020; 37: 101487
  • 78 Filippi M, Preziosa P, Banwell BL. et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain 2019; 142 (07) 1858-1875
  • 79 Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50 (03) 652-657
  • 80 Lin CC, Chiu MJ. Teaching NeuroImage: cervical cord atrophy with dorsal root ganglionopathy in Sjögren syndrome. Neurology 2008; 70 (07) e27
  • 81 Chee CG, Park KS, Lee JW. et al. MRI features of aquaporin-4 antibody-positive longitudinally extensive transverse myelitis: insights into the diagnosis of neuromyelitis optica spectrum disorders. AJNR Am J Neuroradiol 2018; 39 (04) 782-787
  • 82 Yonezu T, Ito S, Mori M. et al. “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler 2014; 20 (03) 331-337
  • 83 Zalewski NL, Morris PP, Weinshenker BG. et al. Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2017; 88 (03) 218-225
  • 84 Flanagan EP, Weinshenker BG, Krecke KN. et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72 (01) 81-87
  • 85 Kitley J, Leite MI, Küker W. et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 2013; 70 (11) 1375-1381
  • 86 Zalewski NL, Krecke KN, Weinshenker BG. et al. Central canal enhancement and the trident sign in spinal cord sarcoidosis. Neurology 2016; 87 (07) 743-744
  • 87 Faig J, Busse O, Salbeck R. Vertebral body infarction as a confirmatory sign of spinal cord ischemic stroke: report of three cases and review of the literature. Stroke 1998; 29 (01) 239-243
  • 88 Premkumar A, Marincola F, Taubenberger J, Chow C, Venzon D, Schwartzentruber D. Metastatic melanoma: correlation of MRI characteristics and histopathology. J Magn Reson Imaging 1996; 6 (01) 190-194
  • 89 Ginat DT, Meyers SP. Intracranial lesions with high signal intensity on T1-weighted MR images: differential diagnosis. Radiographics 2012; 32 (02) 499-516
  • 90 Wiesmann M, Padovan CS, Pfister HW, Yousry TA. Intracranial dural arteriovenous fistula with spinal medullary venous drainage. Eur Radiol 2000; 10 (10) 1606-1609
  • 91 Sechi E, Flanagan EP. Spinal arteriovenous fistula's often misdiagnosed as myelitis; can we stem the flow?. J Neurol Sci 2020; 413: 116868
  • 92 Zalewski NL, Rabinstein AA, Brinjikji W. et al. Unique gadolinium enhancement pattern in spinal dural arteriovenous fistulas. JAMA Neurol 2018; 75 (12) 1542-1545
  • 93 Rykken JB, Diehn FE, Hunt CH. et al. Rim and flame signs: postgadolinium MRI findings specific for non-CNS intramedullary spinal cord metastases. AJNR Am J Neuroradiol 2013; 34 (04) 908-915
  • 94 Madhavan AA, Diehn FE, Rykken JB. et al. The central dot sign: a specific post-gadolinium enhancement feature of intramedullary spinal cord metastases. Clin Neuroradiol 2021; 31 (02) 383-390
  • 95 Savoldi F, Kaufmann TJ, Flanagan EP, Toledano M, Weinshenker BG. Elsberg syndrome: a rarely recognized cause of cauda equina syndrome and lower thoracic myelitis. Neurol Neuroimmunol Neuroinflamm 2017; 4 (04) e355
  • 96 Burns TM, Mauermann ML. The evaluation of polyneuropathies. Neurology 2011; 76 (07, Suppl 2): S6-S13
  • 97 Devinsky O, Cho ES, Petito CK, Price RW. Herpes zoster myelitis. Brain 1991; 114 (Pt 3): 1181-1196
  • 98 Jain KK, Malhotra HS, Garg RK, Gupta PK, Roy B, Gupta RK. Prevalence of MR imaging abnormalities in vitamin B12 deficiency patients presenting with clinical features of subacute combined degeneration of the spinal cord. J Neurol Sci 2014; 342 (1-2): 162-166
  • 99 Larner AJ, Zeman AZ, Allen CM, Antoun NM. MRI appearances in subacute combined degeneration of the spinal cord due to vitamin B12 deficiency. J Neurol Neurosurg Psychiatry 1997; 62 (01) 99-100
  • 100 Kumar N, Gross Jr JB, Ahlskog JE. Myelopathy due to copper deficiency. Neurology 2003; 61 (02) 273-274
  • 101 Berlit P, Ringelstein A, Liebig T. Spinal MRI precedes clinical improvement in subacute combined degeneration with B12 deficiency. Neurology 2004; 63 (03) 592
  • 102 Khan M, Ambady P, Kimbrough D. et al. Radiation-induced myelitis: initial and follow-up MRI and clinical features in patients at a single tertiary care institution during 20 years. AJNR Am J Neuroradiol 2018; 39 (08) 1576-1581
  • 103 Kamtchum Tatuene J, Pignel R, Pollak P, Lovblad KO, Kleinschmidt A, Vargas MI. Neuroimaging of diving-related decompression illness: current knowledge and perspectives. AJNR Am J Neuroradiol 2014; 35 (11) 2039-2044
  • 104 Nagel MA, Forghani B, Mahalingam R. et al. The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology 2007; 68 (13) 1069-1073
  • 105 van Dop WA, Kersten MJ, de Wever B, Hovius JW. Seronegative Lyme neuroborreliosis in a patient using rituximab. BMJ Case Rep 2013; 2013: bcr2012007627
  • 106 Barreras P, Fitzgerald KC, Mealy MA. et al. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology 2018; 90 (01) e12-e21
  • 107 Tyler KL, Pape J, Goody RJ, Corkill M, Kleinschmidt-DeMasters BK. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology 2006; 66 (03) 361-365
  • 108 Giovannoni G. Cerebrospinal fluid analysis. Handb Clin Neurol 2014; 122: 681-702
  • 109 Chow E, Troy SB. The differential diagnosis of hypoglycorrhachia in adult patients. Am J Med Sci 2014; 348 (03) 186-190
  • 110 Seyfert S, Kunzmann V, Schwertfeger N, Koch HC, Faulstich A. Determinants of lumbar CSF protein concentration. J Neurol 2002; 249 (08) 1021-1026
  • 111 Majed M, Fryer JP, McKeon A, Lennon VA, Pittock SJ. Clinical utility of testing AQP4-IgG in CSF: guidance for physicians. Neurol Neuroimmunol Neuroinflamm 2016; 3 (03) e231
  • 112 Reindl M, Schanda K, Woodhall M. et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020; 7 (02) e674
  • 113 Mariotto SGA, Batzu L, Delogu R. et al. Diagnostic relevance of testing MOG-Abs in CSF of seronegative cases. Abstract—5th Congress of the European Academy of Neurology, Philadelphia 2019
  • 114 Waters P, Fadda G, Woodhall M. et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 2020; 77 (01) 82-93
  • 115 Fritz D, van de Beek D, Brouwer MC, Booij J. Whole-body 18F-FDG PET-CT in the diagnosis of neurosarcoidosis. Mayo Clin Proc 2020; 95 (05) 1082-1084
  • 116 Flanagan EP, Hunt CH, Lowe V. et al. [(18)F]-fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc 2013; 88 (11) 1204-1212
  • 117 Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56 (05) 715-719
  • 118 Horta ES, Lennon VA, Lachance DH. et al. Neural autoantibody clusters aid diagnosis of cancer. Clin Cancer Res 2014; 20 (14) 3862-3869
  • 119 Luetmer PH, Lane JI, Gilbertson JR, Bernstein MA, Huston III J, Atkinson JL. Preangiographic evaluation of spinal dural arteriovenous fistulas with elliptic centric contrast-enhanced MR angiography and effect on radiation dose and volume of iodinated contrast material. AJNR Am J Neuroradiol 2005; 26 (04) 711-718
  • 120 Barreras P, Heck D, Greenberg B, Wolinsky JP, Pardo CA, Gailloud P. Analysis of 30 spinal angiograms falsely reported as normal in 18 patients with subsequently documented spinal vascular malformations. AJNR Am J Neuroradiol 2017; 38 (09) 1814-1819
  • 121 Cohen-Gadol AA, Zikel OM, Miller GM, Aksamit AJ, Scheithauer BW, Krauss WE. Spinal cord biopsy: a review of 38 cases. Neurosurgery 2003; 52 (04) 806-815 , discussion 815–816
  • 122 Venkatasubramanian C, Lopez GA, O'Phelan KH, Group EW. Emergency neurological life support: fourth edition, updates in the approach to early management of a neurological emergency. Neurocrit Care 2020; 32 (02) 636-640
  • 123 Brophy GM, Human T. Pharmacotherapy pearls for emergency neurological life support. Neurocrit Care 2017; 27 (Suppl. 01) 51-73
  • 124 Strohm TA, John S, Hussain MS. Cerebrospinal fluid drainage and blood pressure elevation to treat acute spinal cord infarct. Surg Neurol Int 2018; 9: 195
  • 125 Robertson CE, Brown Jr RD, Wijdicks EF, Rabinstein AA. Recovery after spinal cord infarcts: long-term outcome in 115 patients. Neurology 2012; 78 (02) 114-121
  • 126 Abboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016; 22 (02) 185-192
  • 127 Kleiter I, Gahlen A, Borisow N. et al; NEMOS (Neuromyelitis Optica Study Group). Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018; 5 (06) e504
  • 128 Bonnan M, Valentino R, Debeugny S. et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89 (04) 346-351
  • 129 Weinshenker BG, O'Brien PC, Petterson TM. et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46 (06) 878-886
  • 130 Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014; 20 (04) 501-504
  • 131 Jarius S, Ruprecht K, Kleiter I. et al; In Cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13 (01) 280
  • 132 Le Page E, Veillard D, Laplaud DA. et al; COPOUSEP Investigators, West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015; 386 (9997): 974-981
  • 133 Jankovic J, Rey Bataillard V, Mercier N, Bonvin C, Michel P. Acute ischemic myelopathy treated with intravenous thrombolysis: four new cases and literature review. Int J Stroke 2019; 14 (09) 893-897
  • 134 Tahara M, Oeda T, Okada K. et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19 (04) 298-306
  • 135 Cree BAC, Bennett JL, Kim HJ. et al; N-MOmentum Study Investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394 (10206): 1352-1363
  • 136 Pittock SJ, Berthele A, Fujihara K. et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381 (07) 614-625
  • 137 Traboulsee A, Greenberg BM, Bennett JL. et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19 (05) 402-412
  • 138 Jurynczyk M, Messina S, Woodhall MR. et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017; 140 (12) 3128-3138
  • 139 Lopez-Chiriboga AS, Sechi E, Buciuc M. et al. Long term outcomes in myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) associated disorders. JAMA Neurol 2020; 77 (12) 1575-1577
  • 140 Li S, Ren H, Xu Y. et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study. Neurol Neuroimmunol Neuroinflamm 2020; 7 (03) e705
  • 141 Hacohen Y, Wong YY, Lechner C. et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2018; 75 (04) 478-487
  • 142 Durozard P, Rico A, Boutiere C. et al. Comparison of the response to rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 antibody diseases. Ann Neurol 2020; 87 (02) 256-266
  • 143 Rae-Grant A, Day GS, Marrie RA. et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90 (17) 777-788
  • 144 Dubey D, David WS, Reynolds KL. et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 2020; 87 (05) 659-669
  • 145 Gempp E, Blatteau JE. Risk factors and treatment outcome in scuba divers with spinal cord decompression sickness. J Crit Care 2010; 25 (02) 236-242
  • 146 Albuja AC, Qaiser S, Lightner DD. et al. Surfer's myelopathy without surfing: a report of two pediatric patients. Spinal Cord Ser Cases 2017; 3: 17008
  • 147 Nakamoto BK, Siu AM, Hashiba KA. et al. Surfer's myelopathy: a radiologic study of 23 cases. AJNR Am J Neuroradiol 2013; 34 (12) 2393-2398
  • 148 Joseph PJ, Reyes MR. Dorsal column myelopathy following intrathecal chemotherapy for acute lymphoblastic leukemia. J Spinal Cord Med 2014; 37 (01) 107-113
  • 149 Woldeamanuel YW, Hassan A, Zenebe G. Neurolathyrism: two Ethiopian case reports and review of the literature. J Neurol 2012; 259 (07) 1263-1268
  • 150 Siddiqi OK, Kapina M, Kumar R. et al. Konzo outbreak in the Western Province of Zambia. Neurology 2020; 94 (14) e1495-e1501
  • 151 Brinjikji W, Colombo E, Lanzino G. Clinical and angioarchitectural characteristics of spinal vascular malformations of the cervical spine. J Neurosurg Spine 2020; ;Jan 17; 1-8
  • 152 Hegde AN, Mohan S, Lim CC. CNS cavernous haemangioma: “popcorn” in the brain and spinal cord. Clin Radiol 2012; 67 (04) 380-388
  • 153 Groen RJ, van Alphen HA. Operative treatment of spontaneous spinal epidural hematomas: a study of the factors determining postoperative outcome. Neurosurgery 1996; 39 (03) 494-508 , discussion 508–509
  • 154 Dörflinger-Hejlek E, Kirsch EC, Reiter H, Opravil M, Kaim AH. Diffusion-weighted MR imaging of intramedullary spinal cord abscess. AJNR Am J Neuroradiol 2010; 31 (09) 1651-1652
  • 155 Kikuchi S, Shinpo K, Niino M, Tashiro K. Subacute syphilitic meningomyelitis with characteristic spinal MRI findings. J Neurol 2003; 250 (01) 106-107
  • 156 Stich O, Herpers M, Keil A. et al. JC virus myelitis without cerebral involvement in acute myeloid leukemia. Eur J Neurol 2011; 18 (11) e143-e144
  • 157 Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38 (02) 206-216
  • 158 Zhu W, Luo S, Zhu L. Multiple spinal lesions in an immunocompetent young man. JAMA Neurol 2017; 74 (06) 741-742